Tradestie Institutional Equity Comparison Engine
CLYM vs CVM โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
CLYM Overall Edge
CLYM Captures Institutional Edge (3โ1 Pillars ยท 6โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Climb Bio, Inc. Common Stock (CLYM) driven by superior Growth & Margin, Momentum & Technical, Options & Structure while CVM counters with relative strength in Valuation. Fundamentally, CLYM trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus CVM at 23.0x Forward P/E and 0.0% operating margin (-62.7% YoY). In options structure, CLYM sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against CVM sits in BREAKDOWN (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
CVM
CLYM N/M vs CVM 23.0x Fwd P/E
Growth & Margin Winner
CLYM
Op Margin 0.0% vs 0.0% ยท YoY +0.0% vs -62.7%
Momentum & Technical Winner
CLYM
1Y +414.7% vs -73.8% ยท 52W Pos 49% vs 14%
Options & Structure Winner
CLYM
UNCLASSIFIED (N/A IV) vs BREAKDOWN (N/A IV)
CLYM
NASDAQ
Climb Bio, Inc. Common Stock
Pharmaceutical Preparations
$9.78
-1.61% 1D
Market Cap
$608.5M
1M Return
+0.51%
1Y Return
+414.74%
Forward P/E
N/M
Unified AI Score
45.7 / 100
HOLD
Tech 41.0
Fund 47.0
Flow 50.0
Mom 54.0
CVM
NYSE American
Cel-Sci Corporation
Biological Products, (No Disgnostic Substances)
$1.85
+11.45% 1D
Market Cap
$22.5M
1M Return
+12.12%
1Y Return
-73.76%
Forward P/E
23.0x
Unified AI Score
43.5 / 100
HOLD
Tech 23.0
Fund 47.0
Flow 50.0
Mom 54.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
CLYM +414.74%
CVM -73.76%
Spread: +486.79 pp (CLYM Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
CLYM TTM Op. Margin: 0.0%
CVM TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CLYM vs CVM. Trailing 12-month operating profitability (CLYM 0.0% vs CVM 0.0%) and valuation multiples (CLYM N/M vs CVM 23.0x Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | CLYM | CVM | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $608.5M | $22.5M | Larger Scale | CLYM |
| Trailing P/E Ratio Valuation | N/M | 23.0x | Lower Multiple | CVM |
| Forward P/E Ratio Valuation | N/M | 23.0x | Lower Multiple | CVM |
| Revenue Growth (YoY) Growth | +0.0% | -62.7% | Higher Growth | CLYM |
| Operating Margin (TTM) Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -29.3% | -252.5% | Higher ROE | CLYM |
| 52-Week Range Position Momentum | 49% ($2โ$18) | 14% ($1โ$8) | Stronger Trend | CLYM |
| Beta / 30D Volatility Risk Regime | 1.52ฮฒ ยท 112% Vol | 0.42ฮฒ ยท 140% Vol | Lower Realized Risk | CLYM |
| Unified Institutional Score Composite Signal | 45.7 / 100 (HOLD) | 43.5 / 100 (HOLD) | Higher Composite | CLYM |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full CLYM vs CVM Buy Guide
CLYM
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
CVM
BREAKDOWN
29d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither CLYM nor CVM registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.